12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Perjeta pertuzumab regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of breast cancer drug Perjeta pertuzumab from Roche for its approved indication. In March, the European Commission approved Perjeta in combination with the pharma's Herceptin trastuzumab and docetaxel to treat HER2-positive metastatic or locally recurrent unresectable breast cancer in patients who have not received previous anti- HER2 therapy or chemotherapy. NICE said the magnitude of the overall survival (OS) benefit of Perjeta when added to Herceptin and docetaxel was...

Read the full 389 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >